As the most widely investigated marker, tumor PD-L1 expression might be useful as a predictive marker of response to anti-PD-1 treatment for non-small cell lung cancer (NSCLC), gastric cancer and gastroesophageal junction tumors [14, 15]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.